



# Your Participation Matters in **Cancer Research**

 NEARLY  
**400** CLINICAL TRIALS  
IN MORE THAN **30** TUMOR TYPES

Through our  
**Keynote Oncology Clinical Trials**,  
we are studying an investigational  
immunotherapy that works by  
blocking the PD-1 pathway in  
multiple cancer types.




Visit the Merck & Co., Inc. **Booth XX#** for more information.

For more information about this ongoing research  
and to see if your patients may qualify, visit

**[keynoteclinicaltrials.com](http://keynoteclinicaltrials.com)**

# Explore Our Currently Active Trials

We are currently evaluating the safety and efficacy of pembrolizumab in multiple types of cancer (alone and in combination with other therapies). Future clinical trials may be conducted for additional cancers.



**We currently have active trials in the following cancer types:**

- |                 |                |
|-----------------|----------------|
| ■ Bladder       | ■ Liver        |
| ■ Breast        | ■ Lung         |
| ■ Colorectal    | ■ Melanoma     |
| ■ Esophageal    | ■ Pediatric    |
| ■ Gastric       | ■ Prostate     |
| ■ Head & Neck   | ■ Solid Tumors |
| ■ Hematological |                |
| ■ Kidney        |                |

Visit the Merck & Co., Inc. **Booth XX#** for more information.

For more information about our ongoing research and to see if your patients may qualify, visit [keynoteclinicaltrials.com](http://keynoteclinicaltrials.com)